Unlike EGFR‐mutant tumours, which exhibit relatively uniform biology and high therapeutic sensitivity, KRAS‐mutant NSCLC is characterised by profound molecular heterogeneity, divergent co‐mutational profiles (e.g., STK11, KEAP1), and dynamic crosstalk with the tumour microenvironment (TME). This evidence concerns the gene KRAS and neoplasm.